Tessera Therapeutics Appoints Industry Leaders Elliott Sigal & Mary Rozenman to Board of Directors
Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of Elliott Sigal, M.D., Ph.D. and Mary Rozenman, Ph.D. to the companys Board of Directors.
- Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of Elliott Sigal, M.D., Ph.D. and Mary Rozenman, Ph.D. to the companys Board of Directors.
- Elliott and Mary bring phenomenal leadership, experience, and creativity to Tesseras Board of Directors, said Geoffrey von Maltzahn, Ph.D., CEO and Co-Founder of Tessera.
- Dr. Sigal brings decades of clinical experience in drug discovery, drug development, and corporate strategy to Tesseras Board of Directors.
- Dr. Rozenman brings more than 15 years of scientific expertise, company building, and transactions leadership in the biotech industry to Tesseras Board of Directors.